MX2009004607A - Metodo para administrar un compuesto antitumoral. - Google Patents
Metodo para administrar un compuesto antitumoral.Info
- Publication number
- MX2009004607A MX2009004607A MX2009004607A MX2009004607A MX2009004607A MX 2009004607 A MX2009004607 A MX 2009004607A MX 2009004607 A MX2009004607 A MX 2009004607A MX 2009004607 A MX2009004607 A MX 2009004607A MX 2009004607 A MX2009004607 A MX 2009004607A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- tumours
- pharmaceutically acceptable
- treatment
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un método para tratar a un mamífero incluyendo un ser humano, que sufre de un tumor, que comprende administrar el Compuesto 1 de la fórmula A o una sal farmacéuticamente aceptable del mismo a dicho mamífero por infusión intravenosa, caracterizado porque el Compuesto 1 es administrado convenientemente empleando calendarios particulares, tiempos de infusión y dosis que permiten un tratamiento más eficaz de los tumores. El compuesto 1 de fórmula A es un inhibidor de Aurora, nombre químico N-{5-[(2R)-2-metoxi-2-fenileta noil]-1,4,5,6-tetrahidro-pirrolo[3,4-c]pirazol-3-il}-4-(4-metilpi perazin-1-il)benzamida, y el método de preferencia es para el tratamiento de pacientes que tienen tumores sólidos o tumores malignos hematopoyéticos. También se proporciona el uso del Compuesto 1 ó una sal farmacéuticamente aceptable del mismo, y un vehículo o excipiente farmacéuticamente aceptable en la fabricación de un medicamento para el tratamiento de tumores empleando calendarios particulares, tiempos de infusión y dosis, así como el uso del Compuesto 1 para el tratamiento de tumores en la misma forma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06123440 | 2006-11-03 | ||
| PCT/EP2007/061491 WO2008052931A1 (en) | 2006-11-03 | 2007-10-25 | A method of administering an antitumor compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004607A true MX2009004607A (es) | 2009-05-22 |
Family
ID=38702074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004607A MX2009004607A (es) | 2006-11-03 | 2007-10-25 | Metodo para administrar un compuesto antitumoral. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100256160A1 (es) |
| EP (1) | EP2117539B1 (es) |
| JP (1) | JP5547487B2 (es) |
| CN (1) | CN101588800B (es) |
| AR (1) | AR063459A1 (es) |
| AT (1) | ATE479432T1 (es) |
| AU (1) | AU2007316217A1 (es) |
| BR (1) | BRPI0717998A2 (es) |
| CA (1) | CA2668363A1 (es) |
| CL (1) | CL2007003172A1 (es) |
| DE (1) | DE602007008949D1 (es) |
| EA (1) | EA200970444A1 (es) |
| ES (1) | ES2350803T3 (es) |
| MX (1) | MX2009004607A (es) |
| TW (1) | TW200827361A (es) |
| WO (1) | WO2008052931A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5518062B2 (ja) * | 2008-07-24 | 2014-06-11 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | オーロラキナーゼ阻害剤および抗悪性腫瘍剤を含む治療用組み合わせ |
| WO2010009985A2 (en) | 2008-07-24 | 2010-01-28 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| CN105037399B (zh) * | 2014-04-17 | 2017-04-26 | 深圳永泽医药股份有限公司 | 一类Bcr‑Abl双倍体抑制剂及制备方法与用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2261104C2 (ru) * | 1999-11-15 | 2005-09-27 | Фарма Мар С.А. | Лечение злокачественных опухолей аплидином |
| NZ532349A (en) * | 2001-09-21 | 2007-02-23 | Reddy Us Therapeutics Inc | Methods and compositions of novel triazine compounds |
| US7141568B2 (en) * | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| KR101226631B1 (ko) * | 2004-02-06 | 2013-01-28 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 항암 치료 방법 |
| TW200808311A (en) * | 2006-03-30 | 2008-02-16 | Nerviano Medical Sciences Srl | Use of a kinase inhibitor for the treatment of particular resistant tumors |
-
2007
- 2007-10-25 JP JP2009535056A patent/JP5547487B2/ja not_active Expired - Fee Related
- 2007-10-25 CA CA002668363A patent/CA2668363A1/en not_active Abandoned
- 2007-10-25 DE DE602007008949T patent/DE602007008949D1/de active Active
- 2007-10-25 CN CN2007800405595A patent/CN101588800B/zh not_active Expired - Fee Related
- 2007-10-25 ES ES07821854T patent/ES2350803T3/es active Active
- 2007-10-25 EA EA200970444A patent/EA200970444A1/ru unknown
- 2007-10-25 BR BRPI0717998-7A patent/BRPI0717998A2/pt not_active IP Right Cessation
- 2007-10-25 AU AU2007316217A patent/AU2007316217A1/en not_active Abandoned
- 2007-10-25 EP EP07821854A patent/EP2117539B1/en active Active
- 2007-10-25 AT AT07821854T patent/ATE479432T1/de active
- 2007-10-25 US US12/513,290 patent/US20100256160A1/en not_active Abandoned
- 2007-10-25 MX MX2009004607A patent/MX2009004607A/es active IP Right Grant
- 2007-10-25 WO PCT/EP2007/061491 patent/WO2008052931A1/en active Application Filing
- 2007-10-31 TW TW096140931A patent/TW200827361A/zh unknown
- 2007-11-02 AR ARP070104888A patent/AR063459A1/es not_active Application Discontinuation
- 2007-11-02 CL CL200703172A patent/CL2007003172A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2117539A1 (en) | 2009-11-18 |
| AR063459A1 (es) | 2009-01-28 |
| EA200970444A1 (ru) | 2009-12-30 |
| TW200827361A (en) | 2008-07-01 |
| CL2007003172A1 (es) | 2008-06-27 |
| US20100256160A1 (en) | 2010-10-07 |
| JP5547487B2 (ja) | 2014-07-16 |
| BRPI0717998A2 (pt) | 2013-12-03 |
| EP2117539B1 (en) | 2010-09-01 |
| ES2350803T3 (es) | 2011-01-27 |
| CA2668363A1 (en) | 2008-05-08 |
| CN101588800A (zh) | 2009-11-25 |
| CN101588800B (zh) | 2012-01-04 |
| WO2008052931A1 (en) | 2008-05-08 |
| DE602007008949D1 (de) | 2010-10-14 |
| ATE479432T1 (de) | 2010-09-15 |
| AU2007316217A1 (en) | 2008-05-08 |
| JP2010523470A (ja) | 2010-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| SG166775A1 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| CA2501651A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| PT1765362E (pt) | Composições e métodos para o tratamento de doenças neovasculares | |
| CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
| TW200626159A (en) | Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor | |
| CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
| CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| WO2002089805A3 (en) | Use of regularly scheduled high dose intravenous methotrexate therapy | |
| MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
| MXPA05012675A (es) | Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa. | |
| WO2009019708A3 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
| MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
| MX2009004607A (es) | Metodo para administrar un compuesto antitumoral. | |
| HK1096022A1 (en) | Combination therapy with azd-2171[73] astrazeneca ab s-151 85 södertälje sweden | |
| DE60222383D1 (de) | Medikament zur verabreichung von amifostin und verwandten wirkstoffen | |
| MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |